



February 11, 1998

FEB 18 1998

Linda S. Kahl, Ph.D.
Office of Special Nutritionals
Center for Food Safety and Applied Nutrition
Food and Drug Administration
200 "C" St. S.W. (HFS-450)
Washington, D.C. 20204

Dear Dr. Kahl:

NaturaLife Corporation wishes to notify the Food and Drug Administration that it has, within the past 30 days, commenced marketing a dietary supplement which bears a statement under Section 403(r)(6) of the Federal Food, Drug and Cosmetic Act.

The dietary supplement for which the statement is made is Horsechestnut. The dietary ingredient that is the subject of the statement is Horsechestnut seed. The statement reads as follows:

"Supports healthy circulation in the legs. NaturaLife Horsechestnut (*Aesculus hippocastanum*) extract provides Escin, a saponin that has been shown to support healthy circulation. Escin promotes healthy tone in the veins of the lower extremities."

This statement is accompanied by the required disclaimer which is prominently displayed in bold-faced type.

The information contained in this notice is complete and accurate and the above statement is based on data which renders these statements substantiated, truthful and non-misleading.

Sincerely,

NATURALIFE CORPORATION

Gordon M. Walker
Regulatory Counsel

lre

Gordon\Letter\Kahl-NL-Horsechestnut

97S-0162

LET/407
57222